GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fangzhou Inc (HKSE:06086) » Definitions » Altman Z2-Score

Fangzhou (HKSE:06086) Altman Z2-Score : -7.31 (As of Mar. 27, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Fangzhou Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Fangzhou has a Altman Z2-Score of -7.31, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Fangzhou's Altman Z2-Score or its related term are showing as below:

HKSE:06086' s Altman Z2-Score Range Over the Past 10 Years
Min: -12.1   Med: -11.84   Max: -10.78
Current: -10.78

During the past 4 years, Fangzhou's highest Altman Z2-Score was -10.78. The lowest was -12.10. And the median was -11.84.


Fangzhou Altman Z2-Score Historical Data

The historical data trend for Fangzhou's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fangzhou Altman Z2-Score Chart

Fangzhou Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Altman Z2-Score
-12.10 -11.84 -10.78 -

Fangzhou Semi-Annual Data
Dec21 Dec22 Dec23 Dec24
Altman Z2-Score -12.10 -11.84 -10.78 -

Competitive Comparison of Fangzhou's Altman Z2-Score

For the Pharmaceutical Retailers subindustry, Fangzhou's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fangzhou's Altman Z2-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Fangzhou's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Fangzhou's Altman Z2-Score falls into.


;
;

Fangzhou Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Fangzhou's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.1612+3.26*0+6.72*-1.2839+1.05*0.2474
=-7.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was HK$709 Mil.
Total Current Assets was HK$649 Mil.
Total Current Liabilities was HK$535 Mil.
Retained Earnings was HK$0 Mil.
Pre-Tax Income was HK$-913 Mil.
Interest Expense was HK$-2 Mil.
Total Liabilities was HK$568 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(649.492 - 535.224)/709.035
=0.1612

X2=Retained Earnings/Total Assets
=0/709.035
=0

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-912.703 - -2.388)/709.035
=-1.2839

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(140.617 - 0)/568.418
=0.2474

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Fangzhou has a Altman Z2-Score of -7.31 indicating it is in Distress Zones.


Fangzhou  (HKSE:06086) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Fangzhou Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Fangzhou's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Fangzhou Business Description

Traded in Other Exchanges
N/A
Address
4th Street, Floor 1-2, Building S, Kehui Jingu, No. 99, Science Avenue, Luogang Science City, Huangpu District, Guangdong Province, Guangzhou, CHN
Fangzhou Inc is a online chronic disease management platform in China. It has focus on chronic disease management to address the needs of patients with chronic diseases, such as hypertension, cardiovascular and respiratory chronic diseases. The company provide comprehensive medical services and online retail pharmacy services through Jianke Platform. The principal segment of the group are online retail pharmacy services, comprehensive medical services and customized content and marketing solutions. Key revenue is generated from Online retail pharmacy services.
Executives
Asia Tech Holdings Limited 2201 Interest of corporation controlled by you
Vistra Trust (hong Kong) Limited 2301 Trustee
Crescent China Investment Management Ltd. 2102 Investment manager
Hand David Mckee 2201 Interest of corporation controlled by you
Rojanavanichkul Danai 2201 Interest of corporation controlled by you
Veneto Holdings Ltd. 2201 Interest of corporation controlled by you
Tech-med Cayman Iii Ltd. 2201 Interest of corporation controlled by you
Tech-med Investments (s) Pte. Ltd. 2101 Beneficial owner
Cp Pharmatech Singapore Pte. Ltd. 2101 Beneficial owner
Asia Tech Investments Ltd. 2101 Beneficial owner
Crescent Acso Investment Management Ltd 2201 Interest of corporation controlled by you
Crescent Trident Singapore Pte. Ltd. 2101 Beneficial owner
Xie Fangmin 2201 Interest of corporation controlled by you
Zhou Feng 2201 Interest of corporation controlled by you
Fangrong Management Limited 2101 Beneficial owner

Fangzhou Headlines

No Headlines